Abstract:Lung cancer is the second most common cancer worldwide, with over 2.2 million new cases in 2020 and is the leading cause of cancer-related deaths worldwide. Most lung cancer (80-85%) is non-small cell (NSCLC), comprising mostly adenocarcinoma and squamous cell carcinoma, while roughly 10-15% of lung cancer is small cell lung cancer (SCLC), also termed neuroendocrine lung cancer. Subtype identification is critical for determining treatment, and with limited samples, it is critical to get the most data possible from each tissue section. NSCLC subtypes can be treated with chemotherapy or targeted drugs, whereas SCLC tends to respond best to a combination of chemotherapy and radiation. While there have been many improvements in the detection and treatment of lung carcinoma, the immuno-histochemical (IHC) confirmation of subtype remains a prolonged and often iterative process. To overcome this limitation, we have developed a new IHC approach which uses antibodies labeled with novel photocleavable mass-tags combined with matrix assisted laser desorption ionization (MALDI) mass spectrometry imaging. The approach, termed MALDI-IHC, provides fast (1 hr/cm2 imaging time) and highly multiplexed IHC (100+-plex) without the need for iterative cycling procedures. Here, we present a 20+-plex panel for the determination of subtype in lung cancer. An antibody panel comprised of established clinical biomarkers was developed to differentiate between the lung carcinoma subtypes and provide potentially prognostic information. This included markers for adenocarcinoma (TTF-1, Napsin A), squamous cell carcinoma (p40, CK5), and small cell lung cancer (CD56, Chromogranin A and Synaptophysin), as well as general carcinoma markers for t cells, b cells, macrophages, and fibroblasts These markers were first validated individually by immunofluorescence and then compared to MALDI-IHC on annotated tissues. Here we present an overview of the antibody validation for the 20+-plex lung carcinoma panel. Biomarker presence and peak signal intensity for the various subtypes was then determined using pathologist classified tissues for normal lung, adenocarcinoma, squamous cell carcinoma and small cell lung cancer. We report application of the MALDI-IHC approach to the simultaneous determination of lung carcinoma subtypes on a 99-core human lung tissue microarray (TMA) comprised of normal, normal adjacent, cancer adjacent, and cancerous tissues. Moreover, because MALDI-IHC is a non-destructive process, it can be followed by conventional H&E staining on the same tissue section for accurate co-registration of traditional pathology annotations with the highly multiplexed MALDI-IHC results. In the future, even larger, 100+-plex antibody panels can be used for precision medicine on a wide range of cancers, in order to determine the molecular subtypes and guide treatment paths. Citation Format: Catherine A. Kita, Kristina Schwamborn, Gargey Yagnik, Kenneth J. Rothschild, Mark J. Lim. MALDI-IHC high-plex protein biomarker imaging for fast, non-iterative identification of lung carcinoma subtypes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7088.

MALDI Profiling MS Application to Analysis of Non-small Cell Lung Cancer

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

Identification of serum tumormarkers for diagnosing stage Ⅰ lung squamous cell carcinoma by MALDI-TOF mass spectrometry

Application of Laser Capture Microdissection and Surface-enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Biomarkers for Early Diagnosis of Lung Adenocarcinoma

Molecular tissue profiling by MALDI imaging: recent progress and applications in cancer research

The Application of MALDI-TOF MS in Mining Different Peptides and Proteins from the Sera of Lung-cancer Patients

Non-Small Cell Lung Cancer Detection and Subtyping by UPLC-HRMS-Based Tissue Metabolomics

Proteomic patterns analysis with multivariate calculations as a promising tool for prompt differentiation of early stage lung tissue with cancer and unchanged tissue material

Recent Developments in Profiling and Imaging of Molecules from Tissue Sections by MALDI Mass Spectrometry

Application of Liquid Chip Time-of-flight Mass Spectrometry Technology Profiling in Tumor Clinical Research

MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation

Biofluid Metabolic Profiling for Lung Cancer Screening via Reactive Matrix-Assisted Laser Desorption Ionization Mass Spectrometry

Mass Spectrometry Analysis of CYFRA21-1 Negative Human Lung Squamous Serum Proteins

Ambient mass spectrometry for fast identification of lung cancer

MALDI-MS-based biomarker analysis of extracellular vesicles from human lung carcinoma cells

Application of laser capture microdissection to capture pure cells in lung cancer and their paired normal lung tissues

Direct quantitative profiling of amino acids in tissues for the assessment of lung cancer

Abstract 7088: MALDI-IHC high-plex protein biomarker imaging for fast, non-iterative identification of lung carcinoma subtypes

[Application of SELDI-TOF MS Technology Analyzing Serum Protein Profiling for Distinguishing Laryngeal Carcinoma from Ordinary People].

Proteomic profiles of human lung adeno and squamous cell carcinoma using super-SILAC and label-free quantification approaches